The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.
 
Lisa Bodei
Research Funding - AAA/Endocyte/Novartis; AAA/Endocyte/Novartis; Advanced Accelerator Applications/Novartis; Advanced Accelerator Applications/Novartis; ITM Isotope Technologies Munich; Molecular Targeting Technologies
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis; Clovis Oncology; IBA RadioPharma Solutions; ITM Isotope Technologies Munich; Molecular Targeting Technologies
 
Petr Kavan
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche Canada; Taiho Pharmaceutical
 
Moishe Liberman
Stock and Other Ownership Interests - AssistIQ; Ditch Labs; Endocision
Consulting or Advisory Role - Johnson and Johnson
Patents, Royalties, Other Intellectual Property - Cryobiopsy Device
 
Neil Taunk
Honoraria - Boston Scientific
Consulting or Advisory Role - Boston Scientific
Research Funding - Therapanacea; Varian Medical Systems
Travel, Accommodations, Expenses - Boston Scientific
 
Ur Metser
Employment - POINT Biopharma
Consulting or Advisory Role - POINT Biopharma
 
Daniel Juneau
Honoraria - AAA/Endocyte/Novartis
Consulting or Advisory Role - AAA/Endocyte/Novartis
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Junsheng Ma
Employment - POINT Biopharma
 
Richard Cioci
Employment - POINT Biopharma
Stock and Other Ownership Interests - POINT Biopharma
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; GlaxoSmithKline; Inhibrx; Medison
Research Funding - 23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison